Jennifer Burdman is Managing Director at Sauvegarder Investment Management, focused on intellectual property-based financing, investment and monetization opportunities. She is an IP strategist and executive at biotechnology companies, and former partner in an international law firm. As the former Chief Intellectual Property Officer at a number of biotech startups, she has developed and implemented company IP strategy and counseled executive management and boards of directors on matters relating to the acquisition, protection, licensing, and enforcement of IP rights. Ms. Burdman has been a first-chair trial lawyer in complex, high-stakes litigation in patent infringement, trade secret misappropriation, and disputes involving IP. As a litigator, Ms. Burdman’s noteworthy cases included a jury verdict of patent infringement related to the preservation of soft tissue grafts resulting in over $34 million in damages, a jury verdict of willful misappropriation of trade secrets relating to Kevlar with damages of over $900 million, and the successful defense of The Regents of the University of California against a patent licensee seeking expanded rights of sponsored research and license agreements relating to compounds for the treatment of prostate cancer. Ms. Burdman was named one of the "Top 25 Women Leaders in Biotechnology of 2020"by The Healthcare Technology Report. National Law Journal “Rising Star"(40 under 40) in Washington, D.C. for 2015. Profiled as a Law360 “Rising Star” in 2016; named to Law360’s 2016 Intellectual Property Editorial Advisory Board. Benchmark Litigation’s “Under 40 Hot List” in 2016 and 2017.